Geron Corporation  

(Public, NASDAQ:GERN)   Watch this stock  
Find more results for GERN
-0.03 (-0.66%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.42 - 4.63
52 week 2.60 - 4.67
Open 4.57
Vol / Avg. 1.88M/2.19M
Mkt cap 715.16M
P/E     -
Div/yield     -
EPS -0.01
Shares 158.22M
Beta 2.34
Inst. own 46%
Dec 5, 2015
Geron Corp At American Society of Hematology Annual Meeting - 12:15PM EST - Add to calendar
Nov 18, 2015
Geron Corp at Stifel Healthcare Conference
Nov 5, 2015
Q3 2015 Geron Corp Earnings Call - Webcast
Nov 5, 2015
Q3 2015 Geron Corp Earnings Release
Oct 21, 2015
Geron Corp at Biotechnology Industry Organization (BIO) Investor Forum - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 76.87% -3093.67%
Operating margin 76.41% -3149.35%
EBITD margin - -3145.27%
Return on average assets 69.65% -29.74%
Return on average equity 81.91% -37.45%
Employees 42 -
CDP Score - -


United States - Map
+1-650-4737700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Officers and directors

Hoyoung Huh Ph.D. Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
John A. Scarlett M.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Olivia K. Bloom Chief Financial Officer, Executive Vice President - Finance, Treasurer
Age: 46
Bio & Compensation  - Reuters
Stephen N. Rosenfield J.D. Executive Vice President, General Counsel and Corporate Secretary
Age: 62
Bio & Compensation  - Reuters
Andrew J. Grethlein Ph.D. Executive Vice President - Development and Technical Operations
Age: 50
Bio & Compensation  - Reuters
Melissa A. Kelly Behrs Executive Vice President - Business Development and Portfolio and Alliance Management
Age: 51
Bio & Compensation  - Reuters
Susan M. Molineaux Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Daniel Mark Bradbury Independent Director
Age: 54
Bio & Compensation  - Reuters
Karin Eastham CPA Independent Director
Age: 65
Bio & Compensation  - Reuters
V. Bryan Lawlis Jr., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters